Zinc Oxide Nanoparticle Synergizes Sorafenib Anticancer Efficacy with Minimizing Its Cytotoxicity.

摘要: Cancer, as a group, represents the most important cause of death worldwide. Unfortunately, available therapeutic approaches cancer including surgery, chemotherapy, radiotherapy, and immunotherapy are unsatisfactory represent great challenge many patients have recurrence severe side effects. Methotrexate (MTX) is well-established (antineoplastic or cytotoxic) chemotherapy immunosuppressant drug used to treat different types cancer, but its usage requires high doses causing Therefore, we need novel with antitumor efficacy in addition safety. The aim this study was evaluation zinc oxide nanoparticle (ZnO-NPs) sorafenib alone combination on solid Ehrlich carcinoma (SEC) mice. Sixty adult female Swiss-albino mice were divided equally into 6 groups follows: control, SEC, MTX, ZnO-NPs, sorafenib, ZnO-NPs+sorafenib; all treatments continued for 4 weeks. ZnO-NPs characterized by TEM, zeta potential, SEM mapping. Data showed that synergized therapy execute more effective safer anticancer activity compared monotherapy significant reduction (P < 0.001) tumor weight, cell viability, tissue glutathione amount well increase growth inhibition rate, DNA fragmentation, reactive oxygen species generation, release cytochrome c, expression apoptotic gene caspase-3 tissues minimal changes liver, renal, hematological parameters. suggest might be safe candidate potent anticancer. safety combined treatment may allow use clinical trials.